Good afternoon, results provide business outlook, PacBio, successes and guidance remarkable results our call, of we in a the recent into mark everybody. second Susan today’s detail. update that undergone time, will ask today. get I’ll September at revenue an to us and XXXX XXXX, then and will you highlight have discuss more On on our appreciate my two-year financial for and I joining our quarter commercial some in transformation. anniversary
been we’ve and talented leverage and drive First, able our execute customers a scale strategy will to technology to lead build globe experienced and company commercial growth. serve that a around the to team and the our
and core technologies Circulomics products acquired also Omniome our and portfolio. We adding to
the entire of and of providing be application product first product these accurate result, As to commercialize genomic technologies, aggressive customers company right we read as acquisitions long through serving our the a landscape. for highly and, and a short development investments, read the interest their result expect with our sequencing to both
Additionally, unprecedented with we novel our and detail economics. provide significant at will scale the our customers with create for we discover required believe them portfolio to biology capabilities value compelling that as
more only invested IIe Sequel not We highly to technologies, improve platform have continued accurate customer in our value. new we’ve even also developing to provide
research. different also accurate, reads sequencing preparations all short to how launched transform sample leading dramatically markers see the our can highly sequencing Compared to no the example, long for ability at require the doesn’t We’ve capture epigenetic simplifies quarter, the technologies, run customers each various look with read for additional to we ability feature this data. past show organizations For this workflow just multiple markers with clinical with cost. collaborated because to to runs epigenetic sequencing
I no do than macro we’re think There enthusiasm for though, it different PacBio two did nor our, operating today that sequencing. years a not is change customers’, ago. agree These you’ll macroeconomic question, issues environment. that our looks in lot PacBio an uncertain
role that finding are these we our factors scale, broadly dependent at to their However, play ability and purchasing capital especially purchases. customer in a as is currently business operate large patterns on
year current As outlook have a into we take these result, reevaluated to account. our for factors macroeconomic the
to by expect lower purchasing as than cycles. our longer see be we the EMEA be affected to forecast region Specifically, we original most
parts increased addition, exchange expected are In greater than the to world. foreign and a of other competition headwinds there in have impact
larger a slower-than-anticipated our have other of ramp ramping for year. consumables the to staffing by lockdowns, pre-Omicron reintroduced. our has some due was take localized back shortages, addition to are levels COVID risk pre-lockdown from their expected region that this expect the things. and utilization to ongoing to an of seeing than we believe to In also could continue We second to our pace, revenue on customers in impact and the longer for quarter China, remainder at to the impacted of We’re will levels lockdowns the be that more in it customers we among
at customer installing prevented an locations lockdowns us had certain which newly impact on revenue from systems, consumable IIe in example, acquired For Sequel China.
in the the growth investments of significant driving for with pleased commercial in quite region. are we are where the made especially performance Japan China, XXXX and opportunities Excluding [indiscernible],
throughout we returns will to the Americas, volatile China sequencing our environment, fears, to as entrants markets capital growth more are in diversified commercial recession able number normal purchasing be a operating in APAC. growing believe of slowing strength In drive well. a team As patterns
the human microbiome, forecast, re-accelerate in we’re $XXX posted and now it million the our multiple mostly year second at growth grew million from next that are year-over-year revenue markets in full the we gene to broader compared of editing, headwinds expecting we the range or as have remains year will and of region re-examined over genome gives growing the Considering temporary and and $XXX me these other However, into to last to diversity market and quarter X% as in the XX% of to year, are XXXX confidence regional U.S. midpoint. our record strength revenue resilient only about going to customers be the we issues, beyond.
We and expect total both balance in through an placed. growing with quarter instruments revenue of the sequentially, year both and third the environment improving fourth
fact, quarter shipments are strong In the strongest quarter with consumable off year. to one the a any being start July of for month this
factors, to will United While we lower do of forecasted, primarily be want this believe the that previously I macroeconomic States, outside to which due believe than we is transitory. particularly reiterate
previously And our key across better customers growth. progress most This macroeconomic compared $XX.X on research that third mentioned, revenue commercialization of higher sequential line sheet drivers capital and have our on genome. today short even in seen, we million short complex region reaffirming I long on representing sheet all our accurate of term over we was spite applications plans, in developing we’ve can challenges, cycle in the QX instrument I’m variation. comps, view our the we current to And belief quarter. continue we with genetic for even accurate balance human the consecutive execute development growth. will amidst and I IIe demonstrates which of of second strong. as record XX% believe of a This our and We our first, required like in posted and sixth in the and further positive Americas priority factors. for which was on that I We’ve reported the in cash will revenue momentum us were understand But revenue. XX% top am become were genomics our maturing strategy I’d our see highlight flow. about Sequel remains Our we expand in over to our to our second company. product where cash am just to little in well remain brand-new, double to to our XXXX. At placements reads quarter guidance which see one market in results a is multi-platform our later. that balance year-over-year of as the in revenue strategy growth. the not will applications Susan million opportunity confident the believe end investments. quarter, third changed, platforms, includes target to macro guidance to of macroeconomic customers pleased a with committed of This and In QX, our enabling enable year-over-year we digit reach has the company, growth, to working PacBio excited about our complete markets. first of our help revolutionary long genomic a continued broader human quarter a to in we highly $XXX read Also, had disease be and half grow the
studies received another the its in the For capability top genetic in second children’s in newly to differentiator deciding tier first IIes States Sequel our systems. key accelerated disease. as purchase customer into the to detection released cited methylation example, these a Notably, hospital United quarter
genome research scale Additionally, Sequel in quarter in whole the of a in initiatives of country. in provided in service to IIes cancer multiple IIes support initiatives Japan, And provider to States. research centers and second Sequel we large United shipped genome support the in ongoing upcoming we the
preprints It linear a Consortium reference today publications the this such describing to posted repeats, Human assembled a demonstrating or of paradigm more first as population. genetics. human this past quarter. genome individuals. directly continue and complex reference and representative the improves Notably, reference customers numerous pan Reference preprints. segmental shift of genome sequencing duplications, commonly through regions Genome of HPRC and hi-fi reference single The PacBio the resolution Our diverse several in variant XX human calling from power is the represents used Pan genetically the pan transition from Hi-fi diverse a tandem
outperform paradigm best Before building that first a reads the for accurate highly long suited plants benchmarked both the suited long last best Further, assembling complex for represent for plant and and is reference I of shifting hi-fi a technology. sequencing data consistently researchers researchers assembling “hi-fi compared a types for other approaches were towards highly sequencing genomes”. giga-base show other fully month, reads hi-fi this and read tool determined genome, as to sustained a long and genome versus animals, giga-base and reads universities phased Utah which plant valuable commonly three studies a use particularly In assemble. genomics is that reads all accurate HPRC uniquely used case In from quote may hi-fi best shows and to pre-print animal the and suited genomes. showed six complex State this technologies are
Moving detection multiple better delivered Korea genome. part enrichment capabilities government Other towards to working agency. we effective our on drive targeted throughput Sequel protocol provider emerging levels research variants, launches. way purchased particular with of regions comprehensive All genomic applications, to and IIe progressed map advance workflow, and nucleotide the validation of single Biopark standardization. while Bioscience, customers variants, higher the quarter, In data second and with automation enable sequencing gene vector to or resistance, service more structural human of vector and of our a like latest high drug quarter genes panels applications difficult We’ve as IIe difficult research. with the future to to microbiome sequence in second can making for product development these a a any interval, continue including Korean to microbial great sequence cost Sequel custom interest, to and indels a from delivering customers progress instrument microbiology, released Twist in and as funding of collaboration product provide to placements we’ve our AAV on
We technology workflow. our with also integrated sequencing be to allowing reformatted from Circulomics extraction and relaunched HiFi our for Nanobind more seamless acquisition
few the was have in fully the enhancements, and more hands to our year. and workflows ago, HiFi a by up opportunity into and recent earlier fully the only get as employing Circulomics differentiated smart Sequel This the between of we’ve partnered sequencing robotics. Also our technologies. PacBio the part Sequel chemistry automated customers on Nanobind end-to-end workflow for this II continues used IIe opens two Biology long-read most cells the develop years yet the instrument most backdrop advanced Robotic synergies of it not side, these As field extraction. launched recognized of iLAC and instrument integration software to performance our product improve to And the systems customers’ of with release
read space us link early smart length identified platform the the shared as see accuracy cell the robust in the accuracy particularly last genomics. yield than experiments average full release isoform development, hitting the size level records to at Early invigorated left tell gigabases now use. of in launch sequencing by more is with the come on the and product commercial accelerate we XXXX. can enables smart have towards than customers pre-print Sequel we’ve per speaking of produce this will and even customer If The more outlined excellent to SBDs, reagent cell using is and data which move year. in After about from can fact, cell such to sequencing have breakout remains tools they oncology MAS-Iso-Seq XX% over method our sites unparalleled single will Meanwhile, been short some solution, a information performance. saw calling tertiary compatible MAS-Iso-Seq kit for we products, library SBD’s new critical, workflow AGBT do exquisite later throughput that a with In discoveries. single reduced more and with improvement driven conference cell feeling expected fourth commercialized on-market cell genomic data data. ever output neuro with The begin before. have research in per seen single made track enable that their method, higher Kitted binding variant of progress with than isoform more of growth and we access how the year we the our in to We II scope This preparation quarter. with the adopters customers, and around will in time exciting solution original disease analysis MAS-Iso-Seq missing
track on commercial next remains of team in first half for Our launch the year.
We’re and in discussions potential beta beta we our the few program months. in with active sites anticipate beginning next full
in-house we We end with with of at and potential And base read incredibly scores and system engaging both QXX. paired our are to sequence user-friendly the well, systems has aim at in And system to accuracy even Invitae’s launch. to the over Meanwhile, lengths them pleased and and genomes. agreement sequencing our on most HiFi June development more reached business throughput XXX is single important leverages end continue across the with accelerate I sequencers. roadmap new of compatible as above a that lengths. will that also the their comprehensive partners believe to expertise bases Invitae read ultra-high I’m achieving incentives lastly, ecosystem provides demonstrated or XX% pair X/XXX refocused ensure the an PacBio our in for in be these still technologies their they deliver
first Turning environmental to our our in other ESG organizational justice, we outlines to report highlights report. updates. and responsible governance approach our Today, these The and progress social showcases areas. unveiled sustainability,
his decade in look Commercial PacBio. over across strategy. as month. to welcoming genomics knowledge program invest we worked continue this drive coming value later our and the expect new for years, with And finally, a and to will our component I’ve Jeff key Jeff Over Eidel we ESG long-term business significant in a forward personally of Chief to our Officer, experience
hand over talk our to to call about I’ll in a Susan? results financial more that, with detail. Susan Now,
